MedTrace Logo

Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation

NCT06855758 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-05-20

No results posted yet for this study

Summary

Prospective double blind randomized controlled trial. By randomizing patients undergoing kidney transplantation into a conventional catecholamine drug (dobutamine) blood pressure maintenance group and a terlipressin-complexed dobutamine group, the investigators compared the effect of intraoperative blood pressure maintenance and the dosage of the vasoactive drug, postoperative graft function, delayed graft function, and other related complications between the two groups, in order to demonstrate whether the use of terlipressin for blood pressure regulation during kidney transplantation is superior to the existing treatments.

Conditions

  • Kidney Transplant
  • Delayed Graft Function
  • Intraoperative Hypotension

Interventions

DRUG

terlipressin

Terlipressin was given prior to the opening of the graft circulation (with the possibility of reperfusion hypotension) when the blood pressure is suboptimal and does not respond well to dobutamine or fluid volume resuscitation. 1 mg terlipressin + 100 ml of sodium chloride injections was given for intravenous infusion.

Sponsors & Collaborators

  • Beijing Friendship Hospital

    lead OTHER

Principal Investigators

  • Fushan Xue · Department of Anesthesiology, Beijing Friendship Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-06
Primary Completion
2027-06-30
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06855758 on ClinicalTrials.gov